Abbvie To Acquire Immunogen, Including Its Flagship Cancer Therapy Elahere® (Mirvetuximab Soravtansine-Gynx), Expanding Solid Tumor Portfolio
Abbvie To Acquire Immunogen, Including Its Flagship Cancer Therapy Elahere® (Mirvetuximab Soravtansine-Gynx), Expanding Solid Tumor Portfolio
11/30/23, 12:34 PM
Location
north chicagowalthamIndustry
biotechnology
AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space. Additionally, ImmunoGen's follow-on pipeline of promising next-generation ADCs further complements AbbVie's ADC platform and existing programs.
Company Info
Location
North Chicago, Illinois, United States
Company info
Cerevel Therapeutics is a biopharmaceutical company dedicated to developing therapies for neuroscience. It focuses on curing diseases associated with the central nervous system, specializing in treating disorders such as schizophrenia and epilepsy. Cerevel is known for its innovative approaches to complex neurological conditions. The company went public and was listed on NASDAQ under the ticker symbol CERE.
Unlock Strategic Intelligence with Fundz
Access real-time funding updates, strategic shifts with FundzWatch™, exclusive Family Offices, and more — helping you close deals and seize opportunities faster.
Trusted by sales, BD, and investment teams at Oracle, HubSpot, Affinity, and more.
Related people
RH
RH
RH
RH
MH